drugset / Trial / NCT03037437
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with advanced hepatocellular cancer (HCC).
Timeline
- Start
- 2017-02-16
- Primary completion
- 2025-06-27
- Completion
- 2025-06-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxychloroquine | Small molecule | 400 mg | Oral |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |